GlobeNewswire Inc | Nov 9, 2021 07:30AM EST

November 09, 2021

SAN FRANCISCO, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (Olema or Olema Oncology, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for womens cancers, today announced that management will participate in two upcoming investor conferences in November.

Details for the companys participation are as follows:

-- Event: Jefferies London Healthcare ConferenceDate: Tuesday, November 16, 2021Time: 5:00 p.m. GMT (12:00 p.m. ET / 9:00 a.m. PT)Format: Live Fireside Chat -- Event: 4th Annual Evercore ISI HealthCONx ConferenceDate:Tuesday, November 30, 2021Time: 11:45 a.m. ET (8:45 a.m. PT) Format: Live Fireside Chat

Live webcasts of these presentations may be accessed under the Investors & Media section of Olemas website (www.olema.com) and will be archived for 14 days.

About Olema OncologyOlema Oncology is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for womens cancers. Olemas lead product candidate, OP-1250, is an orally available small molecule with combined activity as both a complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD). It is currently being evaluated as a single agent in an ongoing Phase 1/2 clinical trial in patients with recurrent, locally advanced or metastatic ER-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer. Olema is based in San Francisco and has operations in Cambridge, Massachusetts.

ContactEva StroynowskiVice President, Communications and Investor Relationseva@olema.com